ClinicalTrials.gg
Sign In
CompletedNCT07610460QThy2Dvc3DUpdated May 28, 2026

Thyroid Uptake Quantification Validation on a Three-dimensional (3D) Cadmium-Zinc-Telluride (CZT) New Generation Gamma Camera

An observational study in Hypo or Hyperthyroidism, sponsored by Centre Hospitalier Princesse Grace. Completed at 1 site in Monaco. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Centre Hospitalier Princesse Grace · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
27
Ages
18 Years and older
Sex
All
01

Study summary

Thyroid scintigraphy using technetium-99m (99mTc) pertechnetate is traditionally performed using planar imaging to estimate thyroid uptake. Recent developments in quantitative SPECT/CT allow direct activity quantification from three-dimensional tomographic acquisitions. The aim of this study was to evaluate the accuracy of thyroid uptake quantification obtained from 3D SPECT/CT compared with conventional planar image.

Read the detailed description

Planar and SPECT/CT scintigraphy will be performed on a new generation 3D CZT gamma camera and thyroid uptake (TU) value will be calculated on planar acquisition for 27 consecutive patients referred in the department of the investigators for hyper or hypothyroidism.

With a quantitative approach using attenuation, scatter correction and iterative algorithm (12 iterations and 8 subsets) with post filter Median Full Width at Half Maximum (FWHM=3), the TU value with SPECT or SPECT/CT acquisitions can be calculate.

The objective will be to evaluate the potential of a new 3D CZT gamma camera to estimate the thyroid uptake on SPECT (Tomography without attenuation correction) and SPECT/CT (tomography with attenuation correction) acquisitions compared with standard planar scintigraphy as a gold standard.

To established this study it will be necessary to introduce cross-calibration factors performed from homogeneous phantoms, for planar and 3D SPECT acquisitions, to estimate the thyroid uptake values.

02

Conditions studied

  • Hypo or Hyperthyroidism

Keywords

  • thyroid
  • uptake
  • quantification
  • CZT
  • Planar
  • 3D gamma camera
  • SPECT/CT
03

In context

Hyperthyroidism

112 studies on the registry are indexed under Hyperthyroidism; 27 are open to participants now.

This study's enrollment of 27 is below the median of 98 across 48 observational studies indexed under Hyperthyroidism.

Browse Hyperthyroidism studies →

Lead sponsor

Centre Hospitalier Princesse Grace is the lead sponsor of 19 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

No selection it's 27 consecutive patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • hypothyroidism
  • hyperthyroidism

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
27 participants (actual)
Patient registry
No

Interventions

  • OtherNo Intervention: Observational Cohort

    Planar and SPECT/CT acquisitions

06

What researchers measure

Primary outcomes

  1. Quantification of thyroid uptake on a 3D CZT gamma camera

    Time frame: Day 1

07

Study locations

1 site
  • Centre Hospitalier Princesse Grace
    Monaco, 98000, Monaco
08

References and documents

Publications

  • Serrano B, Amblard R, Beaumont T, Hugonnet F, Dietz M, Berthier F, Garnier N, Villeneuve R, Nataf V, Mocquot F, Montemagno C, Faraggi M, Paulmier B. Quantitative analysis of 99mTc-pertechnetate thyroid uptake with a large-field CZT gamma camera: feasibility and comparison between SPECT/CT and planar acquisitions. EJNMMI Phys. 2023 Jul 31;10(1):45. doi: 10.1186/s40658-023-00566-3. PubMed 37522931 ↗
  • Mariani G, Tonacchera M, Grosso M, Orsolini F, Vitti P, Strauss HW. The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism. J Nucl Med. 2021 Mar;62(3):304-312. doi: 10.2967/jnumed.120.243170. Epub 2020 Oct 2. PubMed 33008929 ↗
  • Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Lulaj E, Luster M, Piccardo A, Schmidt M, Tulchinsky M, Verburg FA, Wolin E. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2514-2525. doi: 10.1007/s00259-019-04472-8. Epub 2019 Aug 7. PubMed 31392371 ↗
  • Gnesin S, Leite Ferreira P, Malterre J, Laub P, Prior JO, Verdun FR. Phantom Validation of Tc-99m Absolute Quantification in a SPECT/CT Commercial Device. Comput Math Methods Med. 2016;2016:4360371. doi: 10.1155/2016/4360371. Epub 2016 Dec 14. PubMed 28096891 ↗
  • Ritt P, Vija H, Hornegger J, Kuwert T. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S69-77. doi: 10.1007/s00259-011-1770-8. Epub 2011 Apr 12. PubMed 21484383 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Mar 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 28, 2026
StartActual
Oct 1, 2025
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07610460
Lead sponsor
Centre Hospitalier Princesse Grace
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Oct 1, 2025
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
May 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hyperthyroidism →

Other studies from this sponsor

Centre Hospitalier Princesse Grace

Start the discussion